Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06002477 · ClinicalTrials.gov registry record · Early Phase 1
Attentional Mechanisms in SCD
A Early Phase 1 study of Subjective Cognitive Decline, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06002477 is a Early Phase 1 study of Subjective Cognitive Decline that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 80 participants, above the 72-participant average among 6 other Subjective Cognitive Decline trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06002477, a Early Phase 1 study of Subjective Cognitive Decline, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.
Conditions Studied
Interventions
- DRUG Mecamylamine Challenge
- OTHER Placebo Comparator Challenge
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2028-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06002477
The ClinicalTrials.gov registry entry for NCT06002477 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 6 other Subjective Cognitive Decline trials with a reported enrollment target (11% higher). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Subjective Cognitive Decline appearing as the primary indexed condition, and to 2 interventions - of which Mecamylamine Challenge is the first listed.
NCT06002477 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06002477 about?
NCT06002477 is a clinical study titled "Attentional Mechanisms in SCD". This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic funct...
What is the current status of trial NCT06002477?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2025-03-27. Estimated completion is 2028-06-30.
What conditions does trial NCT06002477 study?
This clinical trial studies the following conditions: Subjective Cognitive Decline.
What interventions are being tested in trial NCT06002477?
The interventions under investigation include: Mecamylamine Challenge (DRUG), Placebo Comparator Challenge (OTHER).
Who is sponsoring clinical trial NCT06002477?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06002477 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subjective Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Internet-based Mind-Body Training for Brain Health
RECRUITING · NA
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
Developing a Peer Support Intervention for Depression in SCD
RECRUITING · NA
-
The Brain Health Champion Study
ACTIVE NOT RECRUITING · NA
-
Brain Health Together: Development and Pilot Test
COMPLETED
-
DEMA-Pro Intervention for Seniors With Subjective Cognitive Decline and Living at Home
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.